Physician profile
Robert S Tuck
NPI 1316025307
$799.08
in general payments reported to CMS, 2019-2025
15 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2020: $30.13 · 2021: $93.51 · 2022: $96.38 · 2023: $119 · 2024: $140 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $397.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $396.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $165.03 | 2019-2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $131.26 | 2019-2024 | Xarelto |
| Pfizer INC. | $82.57 | 2019-2025 | |
| Mylan Specialty L.P. | $75.24 | 2019-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $69.01 | 2019-2021 | |
| Abbvie INC. | $66.25 | 2023-2024 | Dalvance |
| Astrazeneca Pharmaceuticals Lp | $59.92 | 2019-2024 | Farxiga |
| Melinta Therapeutics, LLC | $27.60 | 2019 | |
| Viatris Specialty LLC | $22.32 | 2025 | Yupelri |
| Medtronic, INC. | $20.04 | 2024 | Linq II |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.53 | 2025 | Jardiance |
| Vertex Pharmaceuticals Incorporated | $18.01 | 2025 | |
| Intuitive Surgical, INC. | $15.34 | 2024 | |
| Gilead Sciences, INC. | $14.58 | 2025 | Veklury |
| Merck Sharp & Dohme LLC | $12.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Tuck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.